Cubist Pharmaceuticals
Defunct American pharmaceutical company / From Wikipedia, the free encyclopedia
Cubist Pharmaceuticals was an American biopharmaceutical company that targeted pathogens like MRSA.
Quick Facts Company type, Traded as ...
Company type | Subsidiary (formerly: Public) |
---|---|
Nasdaq: CBST | |
Industry | Pharmaceuticals (Biopharmaceuticals & Biotherapeutics) |
Founded | 1992 |
Defunct | 2015 |
Headquarters | Lexington, Massachusetts |
Key people | Robert J. Perez, President, CEO; |
Products | Product Pipeline |
Revenue | $926.4 million USD (2012) |
Parent | Merck & Co. |
Website | www.cubist.com |
Close
.[1] The company employed 638 people, mostly in Lexington, MA.[2] On 8 December 2014, Merck & Co. acquired Cubist for $102 per share in cash ($8.4 billion).[3]